Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$30.23
+7.6%
$30.91
$13.74
$70.43
$6.50B2.3513.81 million shs16.15 million shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$6.37
-2.5%
$6.93
$3.90
$15.00
$82.38M0.73137,837 shs75,057 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,197.88
+0.2%
$1,140.74
$623.78
$1,249.45
$1.13T0.512.42 million shs1.59 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$49.63
+1.8%
$46.46
$35.12
$71.28
$217.76B0.778.54 million shs6.80 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
+7.55%-7.53%-10.74%+8.07%-47.43%
Lifevantage Corporation stock logo
LFVN
Lifevantage
-2.45%+1.76%-3.78%+22.74%-53.54%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.14%+4.45%-0.72%+37.03%+47.57%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+1.78%+0.03%+3.37%+20.51%-30.75%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$30.23
+7.6%
$30.91
$13.74
$70.43
$6.50B2.3513.81 million shs16.15 million shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$6.37
-2.5%
$6.93
$3.90
$15.00
$82.38M0.73137,837 shs75,057 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,197.88
+0.2%
$1,140.74
$623.78
$1,249.45
$1.13T0.512.42 million shs1.59 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$49.63
+1.8%
$46.46
$35.12
$71.28
$217.76B0.778.54 million shs6.80 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
+7.55%-7.53%-10.74%+8.07%-47.43%
Lifevantage Corporation stock logo
LFVN
Lifevantage
-2.45%+1.76%-3.78%+22.74%-53.54%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.14%+4.45%-0.72%+37.03%+47.57%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+1.78%+0.03%+3.37%+20.51%-30.75%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.19
Hold$31.433.99% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
2.00
Hold$5.00-21.51% Downside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,283.647.16% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.13
Hold$65.5632.11% Upside

Current Analyst Ratings Breakdown

Latest HIMS, LFVN, LLY, and NVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Boost Price TargetHold$23.00 ➝ $27.00
7/23/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Boost Price TargetNeutral$28.00 ➝ $35.00
7/20/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Reiterated RatingSell (D+)
7/20/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Reiterated RatingNeutral
7/15/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,500.00 ➝ $1,600.00
7/14/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOutperform$1,300.00 ➝ $1,385.00
7/14/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOutperform$1,300.00 ➝ $1,385.00
7/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,250.00 ➝ $1,425.00
7/13/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
UpgradeStrong SellHold
7/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,235.00 ➝ $1,273.00
7/13/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
DowngradeHoldStrong Sell
(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$2.35B2.98$0.90 per share33.56$2.38 per share12.70
Lifevantage Corporation stock logo
LFVN
Lifevantage
$228.53M0.35$1.07 per share5.94$2.75 per share2.32
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B17.31$25.18 per share47.58$28.07 per share42.67
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.74$4.77 per share10.40$6.58 per share7.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$128.37M-$0.09N/A58.1379.05-0.56%6.10%1.52%8/10/2026 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.81M$0.4514.169.80N/A2.94%23.89%12.47%9/3/2026 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1542.5526.631.4834.98%105.77%23.76%8/5/2026 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.2611.6515.184.4537.23%63.31%22.19%8/5/2026 (Estimated)

Latest HIMS, LFVN, LLY, and NVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-$0.07N/AN/AN/A$698.90 millionN/A
8/5/2026Q2 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.06N/AN/AN/A$20.69 billionN/A
8/5/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.7680N/AN/AN/A$10.89 billionN/A
5/11/2026Q1 2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.04-$0.40-$0.44-$0.40$616.84 million$608.10 million
5/6/2026Q3 2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.12-$0.04$0.11$47.77 million$43.72 million
5/6/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.203.15%N/A44.44%3 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.58%+15.18%24.58%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.753.51%+21.74%41.08%N/A

Latest HIMS, LFVN, LLY, and NVO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/22/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.63%8/14/20268/14/20269/10/2026
4/27/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.052.12%6/1/20266/1/20266/15/2026
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.18
1.69
1.56
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.96
1.04
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.59
0.79
0.56

Institutional Ownership

CompanyInstitutional Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
63.52%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
11.76%
Lifevantage Corporation stock logo
LFVN
Lifevantage
21.95%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2,442231.46 million204.24 millionOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.62 million9.85 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable

Recent News About These Companies

Novo Nordisk A/S - share repurchase programme
Novo Nordisk: Initiating Buy, Calling The Bottom
Lilly Targets Early 2027 Filing for Next Obesity Drug

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Hims & Hers Health stock logo

Hims & Hers Health NYSE:HIMS

$30.23 +2.14 (+7.60%)
Closing price 07/27/2026 03:59 PM Eastern
Extended Trading
$30.04 -0.19 (-0.63%)
As of 07/27/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$6.37 -0.16 (-2.45%)
Closing price 07/27/2026 04:00 PM Eastern
Extended Trading
$6.39 +0.02 (+0.31%)
As of 07/27/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,197.88 +1.85 (+0.15%)
Closing price 07/27/2026 03:59 PM Eastern
Extended Trading
$1,195.00 -2.88 (-0.24%)
As of 07/27/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$49.63 +0.86 (+1.76%)
Closing price 07/27/2026 03:59 PM Eastern
Extended Trading
$49.70 +0.08 (+0.16%)
As of 07/27/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.